Solgate Therapeutics

Solgate is a biotechnology company focused on developing drugs that target solute carrier (SLC) proteins, a large and largely unexploited class of membrane transporters. The company utilizes a proprietary discovery platform that combines fragment-based chemoproteomics, genetic engineering, and high-content screening to identify and develop small molecule modulators of SLC function. Solgate's pipeline targets a variety of therapeutic areas, including neurological, metabolic, and immune-related disorders. Founded as a spin-off from the Research Center for Molecular Medicine (CeMM) and the Institute of Science and Technology (IST) Austria, the company aims to bridge the gap in SLC drug discovery. By leveraging AI-assisted structural modeling and automated screening, Solgate rapidly advances novel chemical matter from hit identification to lead optimization.